Unique ID issued by UMIN | UMIN000042977 |
---|---|
Receipt number | R000049067 |
Scientific Title | Skin irritation patch test to evaluate skin safety of Cannabidiol (CBD) in healthy Female subjects |
Date of disclosure of the study information | 2021/02/15 |
Last modified on | 2021/03/23 21:48:11 |
Skin irritation patch test to evaluate skin safety of Cannabidiol (CBD) in healthy Female subjects
Cannabidiol patch test
Skin irritation patch test to evaluate skin safety of Cannabidiol (CBD) in healthy Female subjects
Cannabidiol patch test
Japan |
Health Female
Adult |
Others
NO
To evaluate the skin safety of CBD with skin irritation patch test in healthy female subject.
Safety
Assessment of skin irritation based on the ICDRG (International Contact Dermatitis Research Group) Standards
Safety: Evaluated for all adverse events
Interventional
Factorial
Randomized
Individual
Double blind -all involved are blinded
Placebo
6
Diagnosis
Food |
CBD concentration 0%
CBD concentration 0.1%
CBD concentration 0.5%
CBD concentration 1.0%
CBD concentration 1.5%
unit only
20 | years-old | <= |
55 | years-old | >= |
Female
1) Female between the Age from 20<= <45 at the time of obtaining consent
2) Those who have the ability to consent, comply with matters to be complied with while participating in the examination, undergo the pre-examination stipulated in this test implementation plan, and can declare subjective symptoms, etc.
3) Those who do not have skin diseases such as dermatitis and eczema at the site where study drug will be administered
4) A person who has no history of rashes caused by bandages and contact dermatitis caused by metal, cosmetics, household products, etc.
5) Those who have a BMI (Body Mass Index) of 18.5 or more and 30.0 or less at the time of screening visit
) Those who have a history of evaluation of this test and considered to have an impact on safety, such as Drug abuse/ dependence, alcohol abuse/ dependence, heart, liver, kidney, lung, eye, blood, digestive diseases, etc.
2) A person who has a history of allergies to drugs or has a specific constitution (Alcohol hypersensitivity, etc.)
3) Those who may use the drug (antihistamines, adrenal cortical hormone agents) within one week before administered the study drug
4) Pregnant or nursing women
5) Those who are within 3 months of participating in other clinical trials
6) In addition, those who are deemed unsuitable for this study by the physician responsible for the research or the doctor sharing the research
10
1st name | Uchida |
Middle name | |
Last name | Naoki |
Showa University School of Medicine
Department of Clinical Pharmacology
157-8577
6-11-11 Kitakarasuyama Setagaya-ku, Tokyo
0333005254
nuchida@med.showa-u.ac.jp
1st name | Uchida |
Middle name | |
Last name | Naoki |
Showa University School of Medicine
Department of Clinical Pharmacology
157-8577
6-11-11 Kitakarasuyama Setagaya-ku, Tokyo
0333005254
nuchida@med.showa-u.ac.jp
Showa University School of Medicine
Department of Clinical Pharmacology
Japan Cosmetics Association
Profit organization
IRB of Showa Univ. Karasuyama Hospital
6-11-11 Kitakarasuyama
0333005247
kawashima@ofc.showa-u.ac.jp
NO
2021 | Year | 02 | Month | 15 | Day |
Published
10
In the range of CBD concentrations of 0% to 1.5%, CBD was not observed of any skin irritating adverse effects.
2021 | Year | 03 | Month | 23 | Day |
Main results already published
2021 | Year | 02 | Month | 12 | Day |
2021 | Year | 02 | Month | 15 | Day |
2021 | Year | 02 | Month | 15 | Day |
2021 | Year | 03 | Month | 31 | Day |
2021 | Year | 01 | Month | 12 | Day |
2021 | Year | 03 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049067
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |